Holen Sie sich die Stockscreener-App
128.97
0.46%
-0.59
Handel nachbörslich:
131.00
2.03
+1.57%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$129.56
Offen:
$130.895
24-Stunden-Volumen:
1.31M
Relative Volume:
0.66
Marktkapitalisierung:
$19.72B
Einnahmen:
$4.29B
Nettoeinkommen (Verlust:
$703.00M
KGV:
28.89
EPS:
4.4635
Netto-Cashflow:
$993.00M
1W Leistung:
+5.83%
1M Leistung:
-3.89%
6M Leistung:
+32.03%
1J Leistung:
+51.93%
1-Tages-Spanne:
$128.60
$132.28
1-Wochen-Bereich:
$118.53
$134.76
52-Wochen-Spanne:
$68.70
$155.53
Illumina Inc Stock (ILMN) Company Profile
Firmenname
Illumina Inc
Sektor
Branche
Telefon
(858) 202-4500
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
128.97 | 19.81B | 4.29B | 703.00M | 993.00M | 4.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
512.69 | 190.90B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
204.73 | 144.26B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
648.70 | 50.60B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.54 | 33.67B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.04 | 30.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Bestätigt | Citigroup | Neutral |
| 2025-02-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-02-10 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-11-12 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-08-28 | Hochstufung | Argus | Hold → Buy |
| 2024-08-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-11-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Eingeleitet | Bernstein | Underperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Neutral |
| 2023-01-25 | Herabstufung | Argus | Buy → Hold |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Perform |
| 2022-12-12 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-04 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Underweight |
| 2020-12-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-10-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Herabstufung | Stifel | Buy → Hold |
| 2020-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2020-09-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term - Nasdaq
DNA Microarray Market is expected to reach US$ 6.12 billion - openPR.com
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
ILMN: Sequencing innovation, clinical growth, and end-to-end solutions drive strong outlook - TradingView
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub - TradingView
ILMN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Handelsbanken Fonder AB Boosts Stake in Illumina, Inc. $ILMN - MarketBeat
Is Illumina’s (ILMN) TruPath Rare Disease Push Reframing Its Clinical Sequencing Investment Narrative? - simplywall.st
Illumina Inc. stock underperforms Monday when compared to competitors - MarketWatch
Illumina Inc (ILMN) Trading Down 2.84% on Mar 2 - GuruFocus
Illumina, Inc. (ILMN) Stock Analysis: Exploring The Upside With A 33% Return On Equity - DirectorsTalk Interviews
Why Illumina (ILMN) Is Up 14.3% After Launching TruPath Genome And Expanding Rare-Disease Sequencing - Yahoo Finance
Illumina: Competitive Pressures Mounting but 2026 Revenue Targets Still Intact, Justifying a Hold Rating - TipRanks
Andra AP fonden Buys 58,209 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Position Boosted by Citigroup Inc. - MarketBeat
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected MultiomicsPR Newswire APAC - PR Newswire Asia
Illumina, Inc. Whole-Genome Sequencing Technology to Accelerate Rare Disease Testing in Florida - marketscreener.com
Primecap Management Co. CA Sells 73,220 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina Inc. Unveils Revolutionary Genomic Advancements - Devdiscourse
[PRNewswire] Illumina Launches TruPath Genome - Yonhap News Agency
What a $75 Million Exit From MDU Might Signal Amid a 24% One-Year Rally - The Motley Fool
The next generation is shaping the future of rare diseases - Illumina
Evercore ISI reiterates Illumina stock rating on competitive positioning - Investing.com
Evercore ISI reiterates Illumina stock rating on competitive positioning By Investing.com - Investing.com India
Canaccord reiterates Illumina stock Hold rating after Roche pricing By Investing.com - Investing.com Canada
Canaccord reiterates Illumina stock Hold rating after Roche pricing - Investing.com
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Present - PharmiWeb.com
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026 - Yahoo Finance
Illumina partners go beyond the genome, driving cancer breakthroughs - marketscreener.com
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics - PR Newswire
Vestmark Advisory Solutions Inc. Sells 22,703 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Shares Bought by North Star Asset Management Inc. - MarketBeat
Illumina Genome Push Raises Questions On Growth, Adoption And Valuation - simplywall.st
Assessing Illumina (ILMN) Valuation After Recent Share Price Rebound And Longer Term Volatility - Yahoo Finance
Illumina (ILMN) Chief Legal Officer sells 1,336 common shares in open market - Stock Titan
Illumina launches TruPath Genome, setting a new standard in genomic insight - Investing News Network
Illumina Launches TruPath Genome Workflow Solution - marketscreener.com
NovaSeq X Series innovation roadmap - Illumina
8,500 Shares in Illumina, Inc. $ILMN Purchased by Monetta Financial Services Inc. - MarketBeat
Next Generation Sequencing Market Competitive Landscape - GlobeNewswire
Illumina, Inc. $ILMN Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Illumina unveils NovaSeq X upgrades with 40% output increase - Investing.com Australia
Illumina, Inc. (ILMN) Stock Analysis: Exploring a 15.62% Potential Upside in the Genomics Sector - DirectorsTalk Interviews
Faster DNA decoding: Illumina’s NovaSeq X gets 40% more data, higher accuracy - Stock Titan
Illumina Beat Q4 Earnings and Closed a $350M Acquisition. Here’s What Investors Need to Know - TIKR.com
Why Illumina Inc. stock is a must watch in 20252025 Support & Resistance & Free Verified High Yield Trade Plans - mfd.ru
Illumina, Inc. $ILMN Shares Sold by Vanguard Group Inc. - MarketBeat
Jupiter Asset Management Ltd. Makes New $16.69 Million Investment in Illumina, Inc. $ILMN - MarketBeat
Scott Davies reports sale of 323 Illumina shares (NASDAQ: ILMN) - Stock Titan
Finanzdaten der Illumina Inc-Aktie (ILMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):